Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report)’s stock price dropped 3.3% during trading on Wednesday . The stock traded as low as $2.30 and last traded at $2.37. Approximately 8,751 shares traded hands during trading, a decline of 85% from the average daily volume of 56,875 shares. The stock had previously closed at $2.45.
Cyclerion Therapeutics Trading Down 3.3 %
The stock has a 50-day simple moving average of $3.05 and a 200 day simple moving average of $2.91.
Cyclerion Therapeutics Company Profile
Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.
Featured Articles
- Five stocks we like better than Cyclerion Therapeutics
- How to Use the MarketBeat Dividend Calculator
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- How Can Investors Benefit From After-Hours Trading
- 3 Steel Stocks Soaring After Tariff Announcements
- Why Invest in 5G? How to Invest in 5G Stocks Â
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
